Senesco Expands On Preclinical Multiple Myeloma Findings

Senesco Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT) announced further details of its continuing preclinical multiple myeloma research. In February 2008, the Company announced results of preclinical animal studies in which Senesco's Factor 5A technology, encapsulated in nanoparticles, was able to induce apoptosis in multiple myeloma tumors when injected intratumorally.

Study Supports Possible Use Of Leukine R As A Potential Adjuvant Therapy For High-Risk Melanoma Patients

Results from an adjuvant trial in high-risk melanoma patients demonstrated that a majority of patients treated with Leukine(R) (sargramostim) achieved disease-free and/or overall survival. These findings, which indicate Leukine's potential in this cancer setting, were released at the 44th annual meeting of the American Society of Clinical Oncology (ASCO).

Scientists Try To Develop Anti-Cancer Meat, Eggs

Imagine the chicken and eggs you eat could be cancer-fighting food. Researchers at Ohio State's Comprehensive Cancer Center say they could be on their way to doing that. Here's the best part - they're only using a natural plant extract, and a little time.

SpePharm Announces The Granting Of National Marketing Authorizations For Loramyc R In Europe And First Launch In The UK

SpePharm Holding B.V., the specialty pharmaceutical company dedicated to the sales and marketing of innovative hospital and specialists products throughout Europe, announced the granting of national approvals of Loramyc in the UK, Denmark, Germany, Belgium, The Netherlands, Luxembourg, Finland and Sweden, as well as in Spain under the trade name Sitamic .

Amgen And Wyeth Statement On The FDA Early Communication About Tumor Necrosis Factor TNF Blockers

Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), issued a statement in response to the Food and Drug Administration (FDA) Early Communication regarding an ongoing safety review of Tumor Necrosis Factor (TNF) blockers (marketed as Remicade, Enbrel, Humira and Cimzia) and the possible association between the use of these medicines and the development of lymphoma and other cancers in children and young adults.

Ipsen And Spirogen's SJG-136 Shows Encouraging Results In The Treatment Of Refractory Solid Tumours At ASCO

Ipsen (Paris:IPN) (Euronext: IPN) and Spirogen Ltd. announced that final results from a Phase I clinical trial of the DNA sequence recognizing minor groove binder SJG-136 sponsored by the US National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) with Ipsen were presented today at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago by Dr.

Calando Pharmaceuticals Doses First Patient In SiRNA Phase I Clinical Trial

Calando Pharmaceuticals, a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), announced that the first patient has successfully completed the first dosing cycle (four doses over two weeks) of CALAA-01 in the first clinical trial using systemically-delivered siRNA to treat cancer.

Malignant Melanoma Classification Given Additional Genetic Component

Existing melanoma classifications have been refined by a team at theUniversity of California San Francisco according to an article releasedon June 2, 2008 in the open access journal PLoS Medicine.Melanoma, a malignant tumor of melanocytes, are presently classified bymorphological means.

Molecular Insight Pharmaceuticals, Inc. Reports Preliminary Results Of Azedra trade; Phase I Trial In Neuroendocrine Cancer Patients At ASCO

Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced positive preliminary results from an ongoing Phase 1 clinical study of Azedra (Ultratrace™ iobenguane I 131 or Ultratrace MIBG) for the treatment of malignant pheochromocytoma, a type of neuroendocrine cancer.

Curis Announces GDC-0449 Phase I Clinical Data Presented At American Society Of Clinical Oncology Annual Meeting 2008

Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop the next generation of proprietary targeted medicines for cancer treatment, announced that a presentation entitled, "A First-in-Human, First-in-Class, Phase I Study of Systemic Hedgehog Pathway Antagonist, GDC-0449, in Patients with Advanced Solid Tumors, " was given by Patricia LoRusso, D.